67 results about "Colon tissue" patented technology

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention belongs to the technical field of biology, and discloses a preparation method of an intestinal plexus patch, which comprises the following steps: killing an intestinal tract donor, fixing intestinal tissue segments of duodenum, jejunum, ileum or colon by using paraformaldehyde, and dehydrating to obtain dehydrated intestinal tissue segments; washing the dehydrated intestinal tissue section and removing mesentery, fat and Pari's lymph nodes attached to the jejunum, cutting an intestinal mass of about 4-6mm perpendicular to the intestinal tissue section, flatly laying the intestinal mass on a glass slide, dropwise adding a PBS (Phosphate Buffer Solution) of Triton X-100, fixing the intestinal mass by using a smooth surface of a pair of tweezers, stripping muscle tissues along the annular muscle direction, and drying the intestinal mass in a drying oven. The intestinal slices with intermuscular nerve plexus are obtained; finally, the intestinal piece with the intermuscular nerve plexus is cleaned, then fluorescent staining and piece sealing are conducted, and the mouse intestinal nerve plexus patch is obtained. The preparation method of the mouse intestinal nerve plexus patch has the advantages of being convenient, rapid and the like.

The application discloses an application of Bacteroides intestinalis in preventing and / or treating ulcerative colitis and belongs to the field of biopharmacy. The application claims the use of Bacteroides intestinalis in preparing a medicine or a composition for preventing and / or treating ulcerative colitis. It is found that Bacteroides intestinalis can significantly inhibit the weight loss of a mouse model of ulcerative colitis, reduce a disease activity index, repair colon tissue damage, and down-regulate the expression level of a proinflammatory factor of the organism, and thus has a clear preventive and / or therapeutic effect on ulcerative colitis and has a good clinical transformation application prospect. Therefore, the Bacteroides intestinalis has a prospect of being developed into a medicine or a composition for preventing and / or treating ulcerative colitis.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

A Lacticaseibacillus rhamnosus MBP01 and a combination thereof for preventing and treating irritable bowel syndrome are provided, which relates to the technical field of microorganism. A deposit number of the Lacticaseibacillus rhamnosus MBP01 is GDMCC NO: 64725. The MBP01 can improve a weight loss trend of IBS model mice, increase food intake and feces water content, alleviate colon tissue damage, downregulate expression levels of IL-1β, TNF-α, PAR-2, and serum CORT and increase an expression level of IL-10. MBP01 with a high concentration can improve an expression level of OCC. Therefore, MBP01 has a certain positive regulatory effect on the intestinal function of IBS model mice and can effectively prevent and treat irritable bowel syndrome.

The present application relates to a new use of halogenophenol compound 4,5,2'-trihydroxy-2,5'-dibromobenzophenone, in particular in the preparation of a drug for treating inflammatory bowel disease. The halogenophenol compound of the present application can significantly alleviate the weight loss and colon shortening of the colonitis model, reduce the disease activity index of the colonitis model, reduce the inflammatory cell infiltration of the colonitis model, reduce the expression of inflammatory factors, has an immune regulation function on the intestinal tract, and is superior to the clinical first-line drug mesalazine in most indicators, and has application prospects in the treatment of inflammatory bowel disease.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention discloses bifidobacterium longum CCFM1509 with autophagy promoting and colon aging resisting functions and application of the bifidobacterium longum CCFM1509, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1509 provided by the invention can relieve colon tissue pathological damage caused by senescence, reduce the level of proinflammatory cytokines in colon tissues, reduce the oxidative stress level in the colon tissues, reduce the level of senescence-related senescence markers in the colon tissues and adjust the autophagy level in the colon tissues. Therefore, the bifidobacterium longum CCFM1509 disclosed by the invention can be widely applied to the field of medicines and is used for preparing pharmaceutical preparations for preventing or treating colon aging and related diseases; meanwhile, the bacillus subtilis can also be used for developing various functional fermented foods, health foods and formula foods for special medical purposes, provides a new microbial solution for promoting intestinal health and delaying colon senescence, and has important development value and wide market prospects.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.

The invention discloses application of ethyl sulfate in preparation of a medicine for preventing and / or treating inflammatory bowel diseases, and belongs to the technical field of medicines. The invention finds that ethyl sulfate has the effect of preventing and / or treating inflammatory bowel disease for the first time: the ethyl sulfate can obviously improve the survival index of an inflammatory bowel disease model mouse and reduce the disease activity index; the symptoms of weight loss, stool character, inflammation-related diarrhea and bloody stool are relieved; the length of colon tissue is improved, and the size and number of tumors in colorectum are reduced; the pharmaceutical composition has the effects of inhibiting the level of proinflammatory cytokines (TNF-alpha, IL-8, IL-1beta and IL-6), recovering the level of anti-inflammatory cytokines (IL-10 and INF-gamma), inhibiting the enzymatic activity of MPO and MDA and improving the enzymatic activity of SOD and GSH-Px, so that the inflammatory reaction and oxidative stress reaction in the inflammatory bowel disease microenvironment are improved, and the pharmaceutical composition has the pharmacological action of preventing and / or treating the inflammatory bowel disease.

The invention discloses an extraction method of hawthorn exosomes and application of the hawthorn exosomes in treatment of DSS-induced colitis, and belongs to the technical field of plant exosomes. The extraction method comprises the steps of raw material treatment, differential centrifugation, membrane filtration, ultracentrifugation enrichment, density gradient purification and desugaring refining, and the high-purity crataegus pinnatifida exosome with the capsule-shaped structure can be obtained. The hawthorn exosome intervenes DSS-induced colitis through preventive intragastric administration (25-50 mg / kg / d), the disease activity index (DAI) can be reduced to 2 or below, the expression quantity of colon tissue TNF-alpha is recovered to the normal level, the IL-1beta inhibition effect is superior to that of a hawthorn extract, and the curative effect is remarkably superior to that of plant exosomes such as rhizoma curcumae longae, tea leaves and black tea. The process is standardized, the curative effect is definite, and a new scheme is provided for colitis treatment.

This invention provides a traditional Chinese medicine composition for treating ulcerative colitis, belonging to the field of traditional Chinese medicine pharmaceutical technology. The composition is obtained through rational formulation based on the principles of syndrome differentiation and treatment in traditional Chinese medicine, specifically composed of Forsythia suspensa, Lilium brownii, Lysimachia christinae, Sesamum indicum, Prickly ash, Pueraria lobata, Centella asiatica, Viola yedoensis, Houttuynia cordata, Portulaca oleracea, Litsea cubeba, Cirsium japonicum, Schizonepeta tenuifolia, Morus alba root, Lophatherum gracile, Lygodium japonicum, and Capsella bursa-pastoris. This invention's composition exhibits significant anti-inflammatory and de-inflammatory effects, and can repair and improve the integrity of colonic tissue structure, enhance intestinal barrier function, and achieve both symptomatic and root-cause treatment of ulcerative colitis. Simultaneously, this invention's composition has a high efficacy and cure rate in treating ulcerative colitis, and significantly alleviates symptoms such as diarrhea, bloody stools, abdominal pain, abdominal distension, anal burning, and tenesmus, greatly reducing patient suffering.

The invention relates to the technical field of microorganisms, and particularly discloses a new application of a known strain lactobacillus plantarum AL4510, namely an application of the known strain lactobacillus plantarum AL4510 in preparation of a product for improving premature ovarian failure. Experiments show that the lactobacillus plantarum AL4510 can improve the ovarian index and function, maintain the normal development of follicles, recover the disordered estrogen level, and relieve the oxidative stress injury of ovarian and colon tissues. Particularly, the improvement effect of the lactobacillus plantarum strain is obviously superior to that of other lactobacillus plantarum strains. Therefore, the lactobacillus plantarum AL4510 and the microbial agent thereof have a good application prospect in preparation of drugs or functional foods for preventing or relieving premature ovarian failure (especially induced by repeated superovulation).

The invention discloses bifidobacterium longum CCFM1508 capable of activating a TFEB-HKDC1 autophagy pathway and application of the bifidobacterium longum CCFM1508 in the aspect of colon aging resistance, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1508 provided by the invention has an autophagy regulation capability and can be used for effectively improving colon aging. Through intervention of the bifidobacterium longum CCFM1508, damage to colon tissue of an aged mouse can be remarkably relieved, activity of aging-related beta-galactosidase is inhibited, cell apoptosis is regulated, the level of proinflammatory cytokines is inhibited, oxidative damage degree in the colon tissue is slowed down, transcriptional levels of aging markers p21 and p53 in the colon tissue are remarkably reduced, an autophagy pathway of TFEB-HKDC1 can be activated, and the anti-aging effect is achieved. The autophagy level of the colon tissue is adjusted, and the colon aging resisting effect is achieved. Therefore, the application range of the bifidobacterium longum as probiotics is expanded, and the bifidobacterium longum has a huge application prospect in relieving colon aging.

The application discloses a prillium fimicola for relieving ulcerative colitis and application thereof, and belongs to the technical field of microorganisms. The prillium fimicola N03 can improve body weight loss and disease activity index increase caused by ulcerative colitis, inhibit colon atrophy, protect the integrity of colon tissue structure, increase the number of goblet cells, reduce the inflammation level in the intestinal tract, can significantly up-regulate the expression of Nrf2 , Gpx2 and Nqo1 in the body of a mouse with colitis, effectively improve the impaired activation of Nrf2 signal pathway in the body of the mouse, and has a good relieving effect on colitis. The prillium fimicola N03 has a very wide application prospect when used for preparing a medicine composition for relieving ulcerative colitis and a fermented food.​​​​​​​​

This invention belongs to the field of bacterial agent preparation and biomedical technology, specifically relating to a strain of *Lactobacillus reuteri*, a bacterial agent, and its application in treating ulcerative colitis. This invention isolated a strain of *Lactobacillus reuteri*, named PFL-2501, and preserved it biologically. The *Lactobacillus reuteri* PFL-2501 exhibits strong gastrointestinal tolerance and high safety, with no hemolytic properties. It can inhibit harmful pathogenic bacteria in the intestine, regulate immune balance, reduce the content of pro-inflammatory factors in colonic tissue, decrease peroxidase activity, increase the level of anti-inflammatory factors, and improve the expression of intestinal tight junction proteins. The results of the examples show that *Lactobacillus reuteri* PFL-2501 and its bacterial agent can reduce weight loss in ulcerative colitis model mice, reduce the disease activity index, prolong colon length, protect the integrity of the colonic mucosa, and reduce inflammatory damage, thereby achieving a significant effect in alleviating ulcerative colitis.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium bifidum PlantBase-931 for removing dampness and aiding weight loss, its fermented products, preparation methods, and applications. Bifidobacterium bifidum PlantBase-931 can increase the levels of GAS and MTL in the blood, strengthen the spleen and stomach, promote the expression of AQP3 and AQP4 in colon tissue, and accelerate the elimination of dampness from the body, thus benefiting obese individuals in their weight loss journey. The PlantBase-931 fermented product is prepared by staged fermentation, spray drying, and vacuum freeze-drying of the composition. The composition consists of the following ingredients in parts by weight: navel orange, hawthorn, grape, lychee, papaya, coix seed, winter melon, white sugar, and purified water. The resulting fermented product can reduce IL-1β inflammation levels in the spleen, repair spleen damage, and improve loose stool symptoms in obese individuals.

The application of a Clematis glauca pectin in the preparation of food with anti-inflammatory effect belongs to the technical field of food processing and health care. The Clematis glauca pectin is obtained by ultrasonic-assisted enzyme extraction and column chromatography purification with Clematis glauca pericarp as raw material. Experiments show that the pectin has significant DPPH free radical, ABTS free radical scavenging capacity and Fe 3+ reducing capacity, and good antioxidant activity. In a DSS-induced mouse colitis model, the pectin can significantly reduce DAI, improve colon shortening, reduce the levels of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-17A) in serum and colon tissue, repair colon mucosal damage, and regulate intestinal flora structure, such as increasing the relative abundance of beneficial bacteria such as Bacteroides and Akkermansia. The present application provides a new way for developing new anti-inflammatory functional food or health care products for assisting the conditioning of colitis.

The present invention relates to the use of Mucor racemosus and a metabolite thereof in the preparation of a drug for preventing and / or treating ulcerative colitis, which belongs to the technical field of biopharmaceuticals. Mucor racemosus CGMCC NO: 40320 and the metabolite 5mc (5-methylcytosine) thereof of the present disclosure can significantly mitigate problems of disease index, body weight loss and reduction in index of immune-related organs (e.g., spleen) in mice with ulcerative colitis disease, can alleviate the occurrence of inflammation in colon tissue, thereby improving the intestinal wall integrity of intestinal tissues, and thus can be used in the preparation of a drug for preventing and / or treating ulcerative colitis. The present disclosure expands the application fields of Mucor racemosus and provides guidance for clinical application of Mucor racemosus in the treatment of colitis.

The application discloses application of Amomum tsao-ko extract in preparation of medicines for preventing and treating chronic alcoholic liver and intestinal injury, and belongs to the technical field of biotechnology. The extract is applied to prevention and / or treatment of alcoholic liver and intestinal injury and liver-intestinal axis disorder caused by long-term drinking, can reduce contents of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in blood plasma, improve liver and colon tissue pathological injury, repair intestinal mucosal barrier, restore liver tissue mitochondrial function and regulate expression of key factors of liver-intestinal axis; and the Amomum tsao-ko extract can effectively reduce the contents of AST and ALT in blood plasma of alcohol-induced alcoholic liver and intestinal injury model mice at a lower dose, significantly improve liver and intestinal tissue pathological injury, correct liver-intestinal axis function disorder and regulate expression of liver-intestinal axis related factors of liver tissue; the raw material of the application is from a natural product, and is convenient to collect and high in safety.

The invention discloses an arbutin analogue, a preparation method thereof and application of the arbutin analogue in preparation of a medicine for treating chronic colitis, and belongs to the technical field of medicines. The arbutin analogue is structurally characterized in that a galactosyl group is connected with a polysubstituted benzene ring through a flexible connecting chain-(CH) n-O-to form a novel structure which is remarkably different from a known compound arbutin. The arbutin analogue is prepared through chemical synthesis, and a pharmaceutical composition containing the arbutin analogue is provided. Pharmacological experiments prove that the representative compounds hydroquinone monogalactoside and 3, 4-dihydroxyphenol galactoside show disease treatment activity obviously superior to that of arbutin in a DSS-induced mouse chronic colitis model, the disease activity index can be effectively improved, and colon tissue damage can be relieved. Therefore, the compound provided by the invention can be used for preparing medicines for preventing and / or treating chronic colitis. Formula (1)

This invention discloses a high-yield γ-aminobutyric acid (GABA)-relieving bacterium for colitis and its application, belonging to the field of microbial technology. The *Bacterium xylanoplastinus* of this invention (… Bacteroides xylanisolvens NSP018 can alleviate weight loss, reduce the disease activity index, increase colon length, and improve colonic tissue damage in mice with ulcerative colitis. The oat arabinoxylan described in this invention has very broad application prospects for preparing pharmaceutical compositions and fermented foods that alleviate ulcerative colitis.

The invention discloses application of yellow tea polyphenol in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of biological medicine preparation, animal experiments prove that the yellow tea polyphenol can reduce the DAI index of DSS-induced colitis mice and relieve weight loss and colon shortening. By adopting the yellow tea polyphenol provided by the invention, inflammatory response, tissue damage and immune disorder related to colitis can be relieved; the pathological state of colon tissue is improved; therefore, the effect of treating and preventing the colitis is achieved, and the traditional Chinese medicine composition has an extremely wide application prospect.

The invention provides application of azadirachtin in preparation of a medicine for treating ulcerative colitis, and relates to the technical field of medicine. The research of the inventor finds that when the azadirachtin is applied to an ulcerative colitis mouse model, disease progression can be remarkably relieved, multiple indexes including weight loss, fecal morphology and intestinal bleeding can be improved, the phenomenon of colon shortening caused by ulcerative colitis can be reversed, inflammatory cell infiltration and intestinal mucosa injury in colon tissue can be reduced, and the ulcerative colitis can be effectively treated. The traditional Chinese medicine composition can be used for preparing medicines for treating ulcerative colitis.

The invention relates to application of miR-145-5P in preparation of a medicine for preventing and / or treating PRV (pseudorabies virus) infection related diseases, and belongs to the field of biological medicines. The miR-145-5p is found to be a key differential expression molecule in the PRV infected piglet lung and colon tissue exosome through high-throughput sequencing for the first time. In-vitro cell experiments prove that up-regulation of the expression of the miR-145-5p can significantly play an antiviral role through double mechanisms of inhibiting PRV virus replication and promoting apoptosis of infected cells, and research results of the invention provide a brand new target and strategy for prevention and treatment of PRV.

The application provides use of an S1PR1 biased agonist in preparation of a drug for treating inflammatory bowel disease. The application proves through animal tests that, compared with a dextran sodium sulfate treated inflammatory bowel disease model group of mice, the colon length of mice added with SAR247799 treatment tends to be normalized, and finally the purpose of treating inflammatory bowel disease is achieved, and the application has a practical popularization and application prospect.

The application discloses a use of a ganoderma lucidum spore and grifola frondosa composition in preparation of a preparation for assisting in relieving colorectal cancer. The composition comprises ganoderma lucidum spore oil, squalene, grifola frondosa extract, selenium-rich yeast and the like, and is prepared into soft capsules by using a cold preparation method. A mouse model experiment induced by AOM / DSS proves that the soft capsules can significantly relieve weight loss of mice, reduce a disease activity index, improve colon shortening, inhibit expression of inflammatory factors TNF-alpha and IL-6 in serum and colon tissues, reduce intestinal inflammatory reactions, repair colon crypt structure and intestinal mucosal damage, down-regulate expression of a proliferation marker Ki 67, up-regulate expression of an apoptosis marker Caspase-3, induce tumor cell apoptosis, regulate intestinal flora structure, restore relative abundance of Bacteroidetes and Firmicutes, and reverse abnormal increase of Verrucomicrobia. The application can act on the whole process from intestinal polyps, precancerous lesions to colorectal cancer development, is safe and stable, can be taken for a long time, and has high application value.